GlyTech, Inc.

Glytech,Inc. Research and Development on glyco-technology

NEWS&TOPICS

Oct 14, 2015 [ NewsRelease ]

Nippon Shokubai and GlyTech Announce to Collaborate on R&D and Nippon Shokubai Subscribe for Shares of GlyTech through Third Party Allotment.

NIPPON SHOKUBAI CO., LTD. (Headquarter: Osaka, Japan, President: Masanori Ikeda, hereinafter “Nippon Shokubai”) and GlyTech, Inc. (Headquarter: Kyoto, Japan, President: Hiroaki Asai, hereinafter “GlyTech”) announce that they have agreed to collaborate on research and development of Glycosylated Somatostatin Analog (hereinafter “G-SRIF”). Based on this agreement with GlyTech, Nippon Shokubai has decided to establish a laboratory of peptide API (active pharmaceutical ingredient) synthesis.

Nippon Shokubai and GlyTech Announce to Collaborate on R&D and Nippon Shokubai Subscribe for Shares of GlyTech through Third Party Allotment.

Jan 10, 2015 [ NewsRelease ]

An article written by GlyTech's CEO Hiroaki Asai and Dr. Izumi Sakamoto
was published in the 31th issue of PHARM TECH JAPAN (No. 1, p119-121).

An article "Oligosaccharide structures and Biopharmaceuticals Part 1" written by GlyTech's Hiroaki Asai and Izumi Sakamoto was published in the 30th issue of PHARMA TECH JAPAN. PHARM TECH JAPAN is known for presenting on the latest ideas, cutting-edge technologies and innovationas covering not only drug manufacturing but also the regulatory issues.

PHARM TECH JAPAN Homepage

Link to 30th Isuue of PHARM TECH JAPANN

Dec 10, 2014 [ NewsRelease ]

An article written by GlyTech's CEO Hiroaki Asai and Dr. Izumi Sakamoto
was published in the 30th issue of PHARM TECH JAPAN (No. 14, p57-60).

An article "Oligosaccharide structures and Biopharmaceuticals Part 1" written by GlyTech's Hiroaki Asai and Izumi Sakamoto was published in the 30th issue of PHARM TECH JAPAN. PHARM TECH JAPAN is known for presenting on the latest ideas, cutting-edge technologies and innovationas covering not only drug manufacturing but also the regulatory issues.

PHARM TECH JAPAN Homepage

Link to 30th Isuue of PHARM TECH JAPANN

Dec 9, 2014 [ NewsRelease ]

An article written by Dr. Izumi Sakamoto was published in the 30th issue
of PHARM TECH JAPAN (No. 11, p61-64).

An article "Chemically synthesized glycoproteins shed light on novel analytical technologies for biopharmaceuticals" written by Acroscale's Izumi Sakamoto was published in the 30th issue of PHARM TECH JAPAN. PHARM TECH JAPAN is known for presenting on the latest ideas, cutting-edge technologies and innovationas covering not only drug manufacturing but also the regulatory issues.

PHARM TECH JAPAN Homepage

Link to 30th Isuue of PHARM TECH JAPANN

Acloscale, Inc. is a wholly owned subsidiary of GlyTech, Inc. and founded in 2014 to develop QC methods for chemically synthesized glycoproteins and the related molecules and offer its analytical services.

Acloscale Homepage (Japanese only)

Oct 8, 2014 [ NewsRelease ]

Luncheon seminar with GlyTech, Inc. at the 51st Japanese Peptide Symposium

Kyoto (Japan), 8th October 2014 – GlyTech, Inc. is scheduled to host a luncheon seminar at the 51st Japanese Peptide Symposium, Japan to be held Oct 22-24, 2014 in Tokushima, Japan.

Luncheon seminar with GlyTech, Inc. at the 51st Japanese Peptide Symposium

Oct 7, 2014 [ NewsRelease ]

Bachem AG and GlyTech, Inc. Announce Co-promotion Agreement

Bachem AG (Bubendorf, Switzerland), the leading peptide manufacturer, and GlyTech Inc. (Kyoto, Japan), the world-leading developer of glycosylated drugs, announced today that they have entered into a co-promotion agreement for GlyTech’s glycosylation technology. As part of the agreement, Bachem will leverage its sales and marketing resources to enhance GlyTech’s partnering efforts and GlyTech will promote Bachem as the partner of choice for manufacture of its glycopeptides and glycoproteins.

Bachem AG and GlyTech, Inc. Announce Co-promotion Agreement

Oct 7, 2014 [ NewsRelease ]

American Peptide Company and GlyTech, Inc. Announce Co-promotion Agreement

American Peptide Company, Inc. (APC) (Vista, CA) a leading peptide manufacturer, and GlyTech Inc. (Kyoto, Japan), a world-leading developer of glycosylated drugs, announced today that they have entered into a co-promotion agreement for GlyTech’s glycosylation technology. As part of the agreement, APC will leverage its sales and marketing resources to enhance GlyTech’s partnering efforts and GlyTech will promote APC as a partner of choice for manufacture of its glycopeptides and glycoproteins.

American Peptide Company and GlyTech, Inc. Announce Co-promotion Agreement.

Sep 1, 2014 [ NewsRelease ]

GlyTech, Inc. to Present at the 66th SBJ Annual Meeting 2014.

Kyoto (Japan), 1st September 2014 - GlyTech, inc. is scheduled to present at the 66th Annual Meeting of the Society for Biotechnology, Japan to be held Sep 9-11, 2014 in Sapporo, Japan.

GlyTech, Inc. to Present at the 66th SBJ Annual Meeting 2014.

Apr 30, 2014 [ NewsRelease ]

GlyTech, Inc. to Present at TIDES 2014

Kyoto (Japan), 30 April 2014 – GlyTech, Inc. is scheduled to present at TIDES 2014 to be held May 12-15, 2014 in Providence, US. During the presentation, an update regarding GlyTech’s technologies will be provided.

GlyTech to Present at TIDES 2014

Apr 09, 2014 [ NewsRelease ]

GlyTech to Present at PEGS (Protein EnGineering Summit) Boston

GlyTech is scheduled to present at PEGS Boston to be held May 5-9, 2014 in Boston, US. During the presentation, an update regarding GlyTech's technologies will be provided.

GlyTech to Present at PEGS (Protein EnGineering Summit) Boston

Jan 31, 2014 [ NewsRelease ]

GlyTech Secures 600 Million JPY in Series A Financing From Japanese Leading Venture Capital Firms

GlyTech Inc. (Kyoto, Japan), a world leading company of glycosylation, today announced that it has raised 600 million JPY in a Series A financing from four venture capital firms, the University of Tokyo Edge Capital Co. Ltd. (UTEC), DBJ Capital Co., Ltd., Mitsui Sumitomo Insurance Venture Capital and Mitsubishi UFJ Capital Co. Ltd.

GlyTech Secures 600 Million JPY in Series A Financing From Japanese Leading Venture Capital Firms

Oct 23, 2013 [ PressRelease ]

GlyTech and Bachem Named Finalist for CPhI Pharma Award for Best Innovation in Process Development.

Kyoto (Japan), 23 October 2013 – On 22th, October 2013 in Frankfurt, Germany, GlyTech and Bachem were selected as one of three finalists for the 2013 CPhI Pharma Award for Best Innovation in Process Development. Although not ultimately winning the award, being selected as a finalist represents significant validation of the value of the technology and collaboration. The award ceremony took place on the same day as part of the annual CPhI Worldwide exhibition, which attracted approximately 30,000 attendees from the pharmaceutical industry.

the 2013 CPhI Pharma Award

Aug 12, 2013 [ NewsRelease ]

Luncheon seminar with GlyTech, Inc. at the 32th Annual meeting of the Japanese Society of Carbohydrate Research

Kyoto (Japan), 12 August 2013 – On 6th, August 2013, Mr. Hiroaki Asai, CEO at GlyTech, Inc. gave a presentation which title was “Industrial applications of Glycans” at Luncheon Seminar hosted by Sumitomo Bakelite Co., Ltd. during the 32th Annual Meeting of the Japanese Society of Carbohydrate Research in Osaka, Japan.

Luncheon seminar with GlyTech, Inc. at the 32th Annual meeting of the Japanese Society of Carbohydrate Research(English)

Luncheon seminar with GlyTech, Inc. at the 32th Annual meeting of the Japanese Society of Carbohydrate Research(Japanese)

july 10, 2013 [ PressRelease ]

Pioneering breakthrough in the chemical synthesis of Interferon β-1a

Bachem and GlyTech achieved a pioneering breakthrough with the successful chemical synthesis of this protein featuring a specific, single glycosylation.

About Bachem
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.

Pioneering breakthrough in the chemical synthesis of Interferon β-1a (135KB)

  • LINKS